All In Biotech

Drug Trial Radar · NCT05646836

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of XmAb24306 in Combination With Cevostamab in Participants With Relapsed/Refractory Multiple Myeloma

A Phase Ib, Open-label, Multicenter Dose-escalation Study to Evaluate the Safety, Pharmacokinetics, and Activity of XmAb24306 in Combination With Cevostamab in Patients With Relapsed/Refractory Multiple Myeloma

Last checked: Nov 19, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

90

Planned (sponsor's estimate)

Start

Mar 21, 2023

Primary completion

Nov 18, 2026

Study completion Nov 18, 2026

Sponsor

Lead sponsor
Genentech, Inc.Roche (Genentech) (RHHBY)
Sponsor type
Industry
First posted
Dec 12, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and activity of XmAb24306 in combination with cevostamab in participants with relapsed/refractory multiple myeloma (R/R MM) who have received a minimum of three prior treatments, including at least one immunomodulatory drug (IMiD), one proteasome inhibitor (PI), and one anti-CD38 monoclonal antibody.

Conditions

  • Multiple Myeloma

Interventions

  • CevostamabDrug

    Cevostamab will be administered intravenously on a 28-day cycle, for up to one year of treatment depending on clinical response.

  • XmAb24306Drug

    XmAb24306 will be administered intravenously on a 28-day cycle, for up to one year of treatment depending on clinical response.

  • TocilizumabDrug

    Tocilizumab will be administered for the treatment of cytokine release syndrome (CRS) when necessary.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants with Adverse Events (AEs)Time frame: Up to approximately 3 years

Locations

13 sites in 7 countries. Site status is shown where the registry gives one.

  • Royal Adelaide Hospital

    Adelaide, South Australia, Australia

  • Peter Maccallum Cancer Centre

    Melbourne, Victoria, Australia

  • Alfred Hospital

    Melbourne, Victoria, Australia

  • Sygehus Lillebaelt - Vejle Sygehus

    Vejle, Denmark

  • Evangelismos General Hospital of Athens

    Athens, Greece

  • University of Athens, Hematological Clinic,

    Athens, Greece

  • Rabin Medical Center-Beilinson Campus

    Petah Tikva, Israel

  • Tel Aviv Sourasky Medical Center PPDS

    Tel Aviv, Israel

  • Oslo University Hospital Rikshospitalet

    Oslo, Norway

  • Severance Hospital, Yonsei University

    Seoul, South Korea

  • Asan Medical Center - PPDS

    Seoul, South Korea

  • Hospital Universitari i Politecnic La Fe de Valencia

    Valencia, Spain

  • Clinica Universidad de Navarra

    Pamplona, Navarre, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.